HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report

Onkologie. 2012;35(12):776-9. doi: 10.1159/000345041. Epub 2012 Nov 20.

Abstract

Background: Collecting duct carcinoma of the kidney (CDC) is a rare cancer associated with bad prognosis and, at present, with no specific effective therapies.

Case report: We report a clinical case with disseminated highgrade CDC presenting with widespread metastasis to both lungs, pelvic bones, axial skeleton, and the central nervous system (posterior fossa, both hemispheres and pituitary-hypothalamic). The primary tumor in the kidney was demonstrated (by fluorescence in situ hybridization and immunohistochemistry with Herceptest (3+ score)) to significantly overexpress HER2. Critically ill at presentation, the patient received oral capecitabine together with double HER2 blockade with both intravenous trastuzumab and oral lapatinib. His clinical response was a dramatic improvement and a progressive decline in the radiological size of all of his multiple cancer lesions.

Conclusion: Double HER2 blockade is an effective therapy in disseminated CDC even in the presence of brain metastases.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Brain Neoplasms / prevention & control*
  • Brain Neoplasms / secondary*
  • Capecitabine
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / secondary*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Injections, Intravenous
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Lapatinib
  • Male
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Trastuzumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Quinazolines
  • Lapatinib
  • Deoxycytidine
  • Capecitabine
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Fluorouracil